Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Moreblossom

Published November 8, 2026 · Updated November 9, 2026

Improved method for the production of lysergic acid diethylamide ( LSD ) and novel derivatives thereof

Read the full story at Moreblossom

A GMP-oriented method for producing lysergic acid diethylamide ( LSD ) from lysergic acid hydrate using diethylamine and T3P, followed by extraction.

Surfaced by this Google Alert

  • LSD